Sunflower Pharmaceutical Group (002737.SZ) announced that the company plans to use its own funds of 60 million yuan to increase the capital of its subsidiary Sunflower Pharmaceutical Group (Jilin) Linjiang Co., Ltd. (referred to as 'Linjiang Sunflower').
Zhongtong Finance APP News, Sunflower Pharmaceutical Group (002737.SZ) announced that the company plans to use its own funds of 60 million yuan to increase the capital of its subsidiary Sunflower Pharmaceutical Group (Jilin) Linjiang Co., Ltd. (referred to as 'Linjiang Sunflower'). After the capital increase, Linjiang Sunflower's registered capital will increase to 0.1 billion yuan.
The announcement shows that Linjiang Sunflower was established in 2002 and completed an acquisition in 2015. It is mainly engaged in pharmaceutical production business, with main products such as Wu Jia Shen Ha Jie Jing, Weitong Ding Capsules, Ginseng Oral Liquid, Heart and Brain Health Capsules, and Ci Wu Yangxin Oral Liquid, which are characteristic varieties in the field of elderly chronic tonic medicine. The company's use of its own funds for this capital increase will help improve Linjiang Sunflower's asset structure, enhance its overall risk resistance, and support the effective implementation of the company's strategic plan in the field of elderly chronic tonic medicine.